There have been no clinically relevant changes in comparison with 2011 apart from new information and new tips with regards to the cure with bisphosphonates and denosumab (see part ‘Bisphosphonates and RANKL Antibody Denosumab’).The lately produced hanging proof from the PARP inhibitor olaparib in breast most cancers patients with BRCA1/two ger